Ascendis Pharma A/S $ 146.91 3.46 (2.41%)
Volume:
232,602
Avg Vol (1m):
193,341
Market Cap $:
7.90 Bil
Enterprise Value $:
6.84 Bil
PE Ratio:
0.00
PB Ratio:
6.92
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 27.94 | ||
| Equity-to-Asset | 0.91 | ||
| Debt-to-Equity | 0.04 | ||
| Debt-to-EBITDA | -0.12 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 41.64 | ||
| Beneish M-Score | -3.96 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -3355.53 | ||
| Net Margin % | -4051.54 | ||
| ROE % | -56.01 | ||
| ROA % | -49.81 | ||
| ROC (Joel Greenblatt) % | -662.07 | ||
| 3-Year Revenue Growth Rate | 20.5 | ||
| 3-Year EBITDA Growth Rate | -23 | ||
| 3-Year EPS without NRI Growth Rate | -24.2 |
ASND
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 6.92 | ||
| PS Ratio | 716.65 | ||
| EV-to-EBIT | -19.53 | ||
| EV-to-EBITDA | -20.07 | ||
| EV-to-Revenue | 676.67 | ||
| Current Ratio | 14.8 | ||
| Quick Ratio | 14.8 | ||
| Days Sales Outstanding | 115.77 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.94 | ||
| Earnings Yield (Greenblatt) % | -5.13 |